Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus paracasei
- Development stage
- Unknown
- Lead developer
- Shanxi Bethune Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacticaseibacillus paracasei is a probiotic bacterium and live biotherapeutic product (LBP) being investigated for the treatment of Type 1 diabetes (T1D). It functions by modulating the gut microbiota to increase systemic levels of L-lactate. This gut-derived lactate promotes the lactylation of the transcription factor CREB1 at the Lys136 residue within regulatory T cells (Tregs). This post-translational modification reprograms a Bcl6-centered transcriptional program that sustains Treg stability and suppressive function, thereby restoring immune tolerance and restraining autoimmune destruction of pancreatic beta cells. Clinical trial data indicates that oral supplementation with L. paracasei is associated with improved C-peptide secretion and better glycemic control in patients with T1D.
- Other names
- Lactobacillus paracasei
02
Targets
BCL6 (B cell lymphoma 6 protein)CREB1 (Cyclic AMP-responsive element-binding protein 1)
Beyond the preview
Go deeper on lacticaseibacillus paracasei.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus paracasei.